Allysta
A privately held, venture-backed clinical-stage biopharmaceutical company developing first-in-class peptide therapeutics focused on ophthalmology and inflammatory/fibrotic and metabolic diseases. The company advances peptide receptor agonists and associated formulations from preclinical studies through IND/clinical-stage trials, with programs including topical ophthalmic and sustained-release systemic formulations.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Topical ophthalmic peptide formulation (preservative-free sterile eye drop)
A sterile, preservative-free topical peptide formulation developed for ocular surface disease to reduce inflammation and promote corneal epithelial regeneration.
Sustained-release systemic peptide formulation (subcutaneous)
An extended-release subcutaneous peptide formulation developed for systemic indications to modulate metabolic, inflammatory and fibrotic processes.
Small-molecule multi-kinase inhibitor (glaucoma development partnership)
A development program providing regulatory and clinical oversight for a small-molecule multi-kinase inhibitor intended to lower intraocular pressure, developed in collaboration with an external developer.
ALY688
ALY688 is a bioengineered synthetic peptide designed to be a potent and specific adiponectin mimetic that works through the same pathways as natural adiponectin to regulate cellular energy utilization, inhibit inflammatory response, and reduce fibrosis.
ALY688ER
An extended release formulation designed for extended delivery of ALY688 throughout the body, acting as a potent and specific activator of adiponectin signaling pathways.
Topical ophthalmic peptide formulation (preservative-free sterile eye drop)
A sterile, preservative-free topical peptide formulation developed for ocular surface disease to reduce inflammation and promote corneal epithelial regeneration.
Sustained-release systemic peptide formulation (subcutaneous)
An extended-release subcutaneous peptide formulation developed for systemic indications to modulate metabolic, inflammatory and fibrotic processes.
Small-molecule multi-kinase inhibitor (glaucoma development partnership)
A development program providing regulatory and clinical oversight for a small-molecule multi-kinase inhibitor intended to lower intraocular pressure, developed in collaboration with an external developer.
ALY688
ALY688 is a bioengineered synthetic peptide designed to be a potent and specific adiponectin mimetic that works through the same pathways as natural adiponectin to regulate cellular energy utilization, inhibit inflammatory response, and reduce fibrosis.
ALY688ER
An extended release formulation designed for extended delivery of ALY688 throughout the body, acting as a potent and specific activator of adiponectin signaling pathways.
Services
Design and execution of Phase 1 through Phase 2b/3 clinical studies including randomized, double-masked, vehicle-controlled trials.
Execution of animal model studies to evaluate efficacy, inflammation, fibrosis, and metabolic endpoints to support IND-enabling decisions.
Development of topical ophthalmic and sustained-release systemic peptide formulations to achieve localized ocular effects or extended systemic exposure.
Design and execution of Phase 1 through Phase 2b/3 clinical studies including randomized, double-masked, vehicle-controlled trials.
Execution of animal model studies to evaluate efficacy, inflammation, fibrosis, and metabolic endpoints to support IND-enabling decisions.
Development of topical ophthalmic and sustained-release systemic peptide formulations to achieve localized ocular effects or extended systemic exposure.
Expertise Areas
- Peptide therapeutics development
- Ophthalmology drug development
- Preclinical translational pharmacology
- Inflammation and fibrosis therapeutics
Key Technologies
- Synthetic peptide receptor agonists
- Sustained-release subcutaneous delivery
- Sterile preservative-free ophthalmic formulation
- In vivo disease models (DMD, NASH, corneal injury)
News & Updates
Announcement of initiation of a randomized, double-masked, vehicle-controlled Phase 2b/3 study enrolling subjects with moderate-to-severe dry eye.
Announcement of dosing first subject in Phase 1 single- and multiple-ascending dose study evaluating safety, pharmacokinetics and biomarkers in obese adults.
Preclinical study in a choline-deficient high-fat diet mouse model reported dose-dependent reductions in liver fat, inflammatory markers and fibrosis compared with vehicle and listed comparator.
Completion and reporting of Phase 1/2a randomized, double-masked, vehicle-controlled study showing ocular tolerability and exploratory efficacy signals in signs and symptoms.
Presentation of preclinical results on peptide analogues in dry eye models at the ARVO annual meeting.
Completed Series A financing rounds with Morningside Venture Investments to fund clinical development programs.
Announcement of initiation of a randomized, double-masked, vehicle-controlled Phase 2b/3 study enrolling subjects with moderate-to-severe dry eye.
Announcement of dosing first subject in Phase 1 single- and multiple-ascending dose study evaluating safety, pharmacokinetics and biomarkers in obese adults.
Preclinical study in a choline-deficient high-fat diet mouse model reported dose-dependent reductions in liver fat, inflammatory markers and fibrosis compared with vehicle and listed comparator.
Completion and reporting of Phase 1/2a randomized, double-masked, vehicle-controlled study showing ocular tolerability and exploratory efficacy signals in signs and symptoms.
Presentation of preclinical results on peptide analogues in dry eye models at the ARVO annual meeting.
Completed Series A financing rounds with Morningside Venture Investments to fund clinical development programs.